Diabetes Canada   Report issue

Foundation Phase 1 Phase 2 Phase 4
Founded: Toronto ON United States (1953)

Organization Overview

First Clinical Trial
2002
NCT02806349
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Canadian Diabetes Association | Diabetes Canada

Active Ingredients

Drugs in Phase 4 Trials (1)

alpha-lipoic acid (1 trial)

Drugs in Phase 2 Trials (5)

acarbose (precose) (1 trial)

ginseng (3 trials)

omega-3 fatty acids (Omacor) (1 trial)

salba (1 trial)

wheat (1 trial)

Drugs in Phase 1 Trials (2)

empagliflozin (jardiance) (2 trials)

vitamin d3 (2 trials)

Drugs in Other Trials (2)

glucose (1 trial)

saskatoon berry (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hypertension (Phase 2)

Hypotension (Phase 2)

Overweight (Phase 2)

Prediabetic State (Phase 4)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 10